Orthopediatrics (KIDS) Rating Lowered to Hold at Zacks Investment Research
Orthopediatrics (NASDAQ:KIDS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.
According to Zacks, “OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. “
Several other research firms have also recently weighed in on KIDS. JMP Securities started coverage on Orthopediatrics in a research note on Wednesday, February 20th. They set an “outperform” rating and a $44.00 target price on the stock. BidaskClub cut Orthopediatrics from a “buy” rating to a “hold” rating in a research note on Thursday, December 27th. Finally, BTIG Research lifted their target price on Orthopediatrics to $37.00 and gave the company a “buy” rating in a research note on Wednesday, January 2nd. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $41.00.
Orthopediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.19) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.19). The firm had revenue of $14.60 million for the quarter, compared to analysts’ expectations of $14.50 million. Orthopediatrics had a negative return on equity of 22.99% and a negative net margin of 20.89%. Orthopediatrics’s revenue was up 24.8% on a year-over-year basis. During the same quarter last year, the business posted ($1.41) EPS. As a group, equities analysts forecast that Orthopediatrics will post -0.41 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in KIDS. Northern Trust Corp grew its stake in Orthopediatrics by 64.0% during the 2nd quarter. Northern Trust Corp now owns 88,863 shares of the company’s stock valued at $2,367,000 after acquiring an additional 34,687 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Orthopediatrics by 20.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 70,225 shares of the company’s stock valued at $2,573,000 after buying an additional 11,931 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Orthopediatrics during the 3rd quarter valued at about $207,000. EAM Investors LLC lifted its holdings in shares of Orthopediatrics by 118.8% during the 3rd quarter. EAM Investors LLC now owns 68,217 shares of the company’s stock valued at $2,499,000 after buying an additional 37,045 shares during the last quarter. Finally, EAM Global Investors LLC acquired a new stake in shares of Orthopediatrics during the 3rd quarter valued at about $1,737,000. 51.70% of the stock is currently owned by institutional investors.
Orthopediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Further Reading: Stop Order Uses For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.